Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
Quick Look: Five NMEs are up for MHLW panel review on May 25: AstraZeneca’s camizestrant, MSD’s clesrovimab, Sobi’s anakinra, Novartis’ remibrutinib, and Sun Pharma’s isotretinoin. The session will also cover label expansions for Tibsovo, Sarclisa, Retevmo, Minjuvi, Tevimbra, Imfinzi, and…
To read the full story
Related Article
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- J&J Seeks Nod for Talvey-Tecvayli Bispecific Combo in Multiple Myeloma
November 4, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…